2024-10-15 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a research-based biopharmaceutical company focused on developing and marketing innovative therapies for a range of diseases. 

**1. Performance Comparison:**

* **Cumulative Return:** ABBV has generated a cumulative return of 152.4%, exceeding the S&P 500 (VOO) return of 135.82%.
* **Performance Gap:** ABBV outperforms the S&P 500 by 16.58 points. This represents a 58.07% position within the historical range of the performance gap between ABBV and the S&P 500, indicating a relatively strong performance compared to its historical performance.

**2. Recent Price Movement:**

* **Closing Price:** $194.19
* **5-Day Moving Average:** $193.87
* **20-Day Moving Average:** $194.26
* **60-Day Moving Average:** $191.73
* **Analysis:** The stock price is currently trading slightly above its 5-day and 20-day moving averages, suggesting a potential short-term upward trend. However, the 60-day moving average sits below the current price, indicating a longer-term downtrend.

**3. Technical Indicators:**

* **RSI:** 51.02, indicating a neutral sentiment. The stock is neither overbought nor oversold.
* **PPO:** -0.14, suggesting a slight bearish signal. The PPO is negative, indicating that the 12-period moving average is below the 26-period moving average, suggesting a potential short-term downward trend.
* **Delta_Previous_Relative_Divergence:** -6.63, indicating a recent short-term downward trend in the stock's performance.
* **Expected_Return:** 1.658710617083333%, representing the potential maximum 5-year expected return over the S&P 500, based on the current investment amount.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Analysis:** AbbVie has consistently exceeded earnings expectations in recent quarters. The latest earnings report (2024-07-25) showed an EPS of 2.65, exceeding the expected EPS of 2.57, demonstrating strong performance. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market is currently experiencing volatility due to several factors, including inflation, interest rates, and geopolitical tensions. However, analysts remain optimistic about AbbVie's long-term growth prospects, citing its strong drug portfolio and pipeline.
* **Analyst Opinions:** Many analysts maintain a positive outlook on ABBV, citing its robust revenue growth, strong dividend yield, and consistent earnings beat.
* **Performance Highlights:** AbbVie's recent success can be attributed to the strong performance of its key drugs, including Humira and Rinvoq. The company is also investing heavily in research and development to expand its product portfolio.

**6. Overall Analysis:**

AbbVie continues to show strong performance, outperforming the S&P 500 with a consistent track record of exceeding earnings expectations. Despite some near-term bearish signals from technical indicators, its robust drug portfolio, strong dividend yield, and investment in R&D suggest a positive outlook for the long-term. 

**7. Recommendation:**

Based on the above analysis, ABBV presents a compelling investment opportunity. Investors seeking long-term growth and a consistent dividend stream may consider adding ABBV to their portfolio. However, it is crucial to conduct thorough research and consider your own investment goals and risk tolerance before making any investment decisions.

**Disclaimer:** This is not financial advice. The information provided in this report is for general knowledge and educational purposes only, and does not constitute investment advice. You should consult with a qualified professional before making any investment decisions. 
